Spruce Biosciences Faces Volatility: Negative P/E, Stock Decline and Investor Worries
Spruce Biosciences faces sharp stock volatility and a negative P/E as it pursues orphan endocrine drugs—investors weigh risky R&D against potential breakthroughs.
2 minutes to read
